Transparency
Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
Commercial Support
For educational activities during the period of 2008-2009, Med-IQ acknowledges commercial support from the following companies:
- Abbott Laboratories
- The Alliance for Better Bone Health
- Boehringer Ingelheim Corporation
- Bristol-Myers Squibb Company
- Cordis Corporation
- CV Therapeutics
- Daiichi Sankyo-Lilly
- Eisai Inc.
- Eli Lilly and Company
- GlaxoSmithKline
- Merck & Co., Inc.
- Ortho-McNeil-Janssen Pharmaceuticals, Inc.
- Procter & Gamble Pharmaceuticals
- Pfizer Inc.
- Roche Pharmaceuticals
- sanofi-aventis
- Sepracor Inc.
- Schering-Plough Corporation
- Shire Pharmaceuticals
- St. Jude Medical
- Takeda Pharmaceuticals North America
- TAP Pharmaceuticals
- Teva Pharmaceuticals US
- The Medicines Company
- UCB
- Vertex Pharmaceuticals
- Watson Pharmaceuticals, Inc.
NOTE: 2008 commercial support funding may have been received by Medical Education Solutions Group (MESG) prior to company name change to Med-IQ
Bookmark These Med-IQ Sites
Med-IQ Specialty Sites
